Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
Kalnisha Naidoo(Breast Cancer Now), Rachael Natrajan(Institute of Cancer Research), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Frances Daley(Breast Cancer Now), Patty T. Wai(Institute of Cancer Research), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Divya Kriplani(Institute of Cancer Research), James Campbell(Proteome Sciences (United Kingdom)), Syed Haider(MRC Laboratory of Molecular Biology), Sarah Maguire(Breast Cancer Now), Anita Grigoriadis(London Cancer), Stephen Chan(Heidelberg University), Tarek M.A. Abdel-Fatah(University of Nottingham), Ian O. Ellis(University of Nottingham), Andrew Tutt(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Andrew R. Green(Nottingham Biomedical Research Centre), Yinyin Yuan(Institute of Cancer Research), Emad A. Rhaka(Nottingham University Hospitals NHS Trust), Hasan Mirza(London Cancer)
Cited by 68
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k